trending Market Intelligence /marketintelligence/en/news-insights/trending/eKqLcWSLQ3S0uh8rHK88AA2 content esgSubNav
In This List

Dechra Pharmaceuticals adds director

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Dechra Pharmaceuticals adds director

Dechra Pharmaceuticals PLC appointed Lisa Bright to the board as a nonexecutive director, effective Feb. 1, 2019.

Bright serves on the board of Ascendis Pharma A/S and has been president, international, at Intercept Pharmaceuticals Inc. since July 2016. She was also previously a vice president at GlaxoSmithKline PLC and Gilead Sciences Inc.

Northwich, U.K.-based Dechra Pharmaceuticals develops veterinary pharmaceuticals and related products for veterinarians worldwide.